# An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.

> **NCT05643560** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 33 (estimated)

## Conditions studied

- Hemophilia A
- Prophylaxis of Bleeding

## Interventions

- **DRUG:** Damoctocog alfa pegol (Jivi, BAY94-9027)

## Key facts

- **NCT ID:** NCT05643560
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-29
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643560, "An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05643560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*